293 Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1, -2 trials through 5 years

Involvement of sensitive or challenging body areas is an important treatment consideration since patients with psoriasis in these can have disproportionately greater burden disease. We assess comprehensive clearance by measuring the ability ixekizumab to achieve complete skin (PASI 100) up 5 years when multiple (scalp, nails, palmoplantar [pp] regions) are involved. Data were integrated from UNCOVER-1 (NCT01474512) and UNCOVER-2 (NCT01597245) trials for treated per label dosing. PASI 100 was assessed subset who achieved site-specific at week 60 among -2 dataset: nail (NAPSI 0, N=123); scalp (PSSI N=189); pp (PPASI100, N=57); & 0 + PSSI N=115); PPASI100, N=50); N=55); nail, N=50). observed. weeks 264 ixekizumab-treated as follows: (74% [57/77], 48% [26/54]); (71% [118/167], 71% [70/99]); (51% [27/53], 43% [12/28]); (78% [53/68], 59% [23/39]; (72% [18/25], 33% [5/15]); (61% [26/43], 61% [11/18]); 63% [5/8]) involvement, respectively. Ixekizumab treats totality a patient’s manner years, even involved concurrently.